Select region:

Clinical trials located in

Nice

Nice city is located in France. Currently, 20 clinical trials are being conducted in this city.

Nice, nestled on the French Riviera, is renowned for its stunning coastline along the Baie des Anges. Founded by the Greeks circa 350 BC, it boasts a rich history evident in its varied architecture and the ancient ruins of Cemenelum. The city’s vibrant culture is celebrated in its numerous museums, including the Matisse Museum, and the lively Promenade des Anglais. Nice’s unique blend of French and Italian influences is also reflected in its culinary delights, making it a melting pot of Mediterranean flavors.

  • CT-EU-00111000

    Oral Azacitidine Maintenance Therapy After CPX-351 for Acute Myeloid Leukemia

    This clinical trial is studying the use of an oral medication called azacitidine as a maintenance treatment for patients with acute myeloid leukemia (AML) who have achieved remission after receiving the chemotherapy drug CPX-351. AML is a type of blood cancer that can develop after receiving chemotherapy or radiation for another disease (called therapy-related AML or t-AML) or can arise from a pre-existing blood disorder (AML with myelodysplasia-related changes or AML-MRC).

    The study aims to see if taking oral azacitidine after achieving remission with CPX-351 can help improve overall survival in patients with these types of AML, as well as in patients with de novo AML (AML that develops without any known cause). Oral azacitidine has been approved by the FDA for use in AML patients who cannot receive intensive curative therapy like a stem cell transplant, but there is limited data on its effectiveness when used specifically after CPX-351 treatment.

    The trial will evaluate how long patients live after starting oral azacitidine maintenance, with survival being measured from the first dose up to 60 months. The safety of long-term oral azacitidine use will also be studied. Patients interested in this trial should speak with their doctor about the potential benefits and risks of participating.

    France
  • CT-EU-00083874

    Study to find the best way to administer pegaspargase in children with acute lymphoblastic leukemia

    This is a study to investigate treatment strategies for children and adolescents diagnosed with acute lymphoblastic leukemia (ALL). The study focuses on evaluating the efficacy of a drug called pegaspargase. The drug works by depriving tumor cells of essential nutrients, contributing to its potential efficacy against ALL in pediatric patients. The study aims to determine the optimal way to administer pegaspargase, comparing a single high dose with two lower doses, with additional doses later in treatment. For those at highest risk, a more intensive treatment plan is being investigated. This includes two larger initial doses, followed by additional doses later in treatment. The study is evaluating factors such as potential serious side effects and overall treatment efficacy.

  • Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    AustriaBelgiumFinlandFranceGermanyHungaryItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • Iptacopan as a new hope for the treatment of paroxysmal nocturnal hemoglobinuria

    In this phase 3 trial, iptacopan’s efficacy and safety are assessed in adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) who switch from standard anti-C5 treatments to iptacopan. The study, involving multiple centers, consists of an initial 8-week screening and a subsequent 24-week treatment phase with iptacopan. The primary focus is to determine if iptacopan can effectively manage PNH while maintaining patient safety. Participants showing benefits from iptacopan after the treatment period have the opportunity to continue in a roll-over extension study, allowing further observation of iptacopan’s long-term impacts.

    FranceGermanyItalySpainUnited Kingdom
  • Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGreeceHungaryItalyNetherlandsPolandPortugalSpainSweden
  • Venetoclax in recurrence of blood cancer after previous stem cell transplantation

    This study aims to investigate the effectiveness and safety of a novel treatment approach, combining the drugs venetoclax and azacitidine, along with donor lymphocyte infusion (DLI) in patients experiencing a relapse of one of two of blood-related disorders: myelodysplastic syndrome (condition where blood cells do not develop properly) or acute myeloid leukemia (bone marrow cells become abnormal and begin to accumulate in excess), following stem cell transplantation. The study involves a group of patients for whom standard treatments have not yielded satisfactory results. The objective is to understand whether the combination of new drugs and donor lymphocyte infusion can effectively control these blood disorders, especially after stem cell transplantation. Researchers are monitoring side effects, assessing disease progression, and determining the safety of the procedure. The results may provide valuable insights into effective therapeutic strategies for these challenging blood-related disorders.
    France
  • Study on luspatercept treatment for Myelodysplastic Syndrome

    This study is looking into a medication named Luspatercept and how safe and effective it is for people who have a blood condition known as lower-risk Myelodysplastic Syndrome, or LR-MDS for short. These individuals often need transfusions or have their blood refreshed with new, healthy red blood cells. The drug will be given at its highest approved dose to see what effect it has. This is being done in a controlled and careful way to make sure everything is safe for the participants in the study. People who are taking part in this study have been identified as having a very low to medium risk according to the International Prognostic Scoring System (IPSS-R). This means their disease isnt considered high-risk, which makes them suitable candidates for this research. The study is open-label, meaning everybody knows what is in the drug they are getting.

    BelgiumCzechiaFranceGermanyItalyPolandSpain
  • Evaluating efinopegdutide treatment for nonalcoholic steatohepatitis

    This clinical trial explores a new treatment for non-alcoholic steatohepatitis (NASH), a liver condition. It tests the safety and effectiveness of efinopegdutide, a medication administered through weekly injections. Participants, diagnosed with NASH but not severe liver damage, will receive either the medication or a placebo. The study aims to improve liver health and assess potential side effects. It prioritizes participant safety and involves regular health monitoring.

    AustriaBelgiumCzechiaFranceHungaryItalyPortugalSpainUnited Kingdom
  • Fianlimab and cemiplimab: a new treatment for melanoma patients

    The study is underway to determine the most effective treatments in preventing the recurrence of melanoma, a form of skin cancer, following surgical removal. The medicines being tested are Fianlimab and Cemiplimab together or another medicine called Pembrolizumab. The trial aims to assess whether the Fianlimab and Cemiplimab combination outperforms Pembrolizumab in preventing cancer recurrence and if patients administered Fianlimab and Cemiplimab live longer. Additionally, the study seeks insights into the impact of treatments on patients’ quality of life, the occurrence of minor or major side effects, and how these drugs behave inside the patient’s body.

    BelgiumCzechiaFranceGermanyGreeceItalyPolandRomaniaSpainUnited Kingdom
  • Evaluating the efficacy of macitentan in the treatment of high pulmonary artery blood pressure

    This study is checking if a 75 mg dose of a medicine called Macitentan can do a better job for patients with a lung condition called Pulmonary Arterial Hypertension (PAH) compared to a 10 mg dose. The main goal is to see if the 75 mg dose can better delay the patient’s first major health event related to PAH. Major events include things like unplanned hospital stays related to PAH, or their PAH getting worse. The researchers will check if patients’ PAH gets worse by looking at things like their physical exercise ability and signs of heart failure. The study also looks at how patients’ symptoms change from day to day.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalSlovakiaSpainSwedenUnited Kingdom
  • Testing gefurilimab treatment in patients with myasthenia gravis

    This study is looking at a potential treatment for a disease called generalized myasthenia gravis (gMG) in adults. It’s called gefurulimab (ALXN1720). For our study, researchers will divide participants into two groups, each of which will be treated differently. One group will receive the new drug. Importantly, the researchers conducting the study will not know who received which treatment. This ensures the fairness and accuracy of the results. Participants’ health will be closely monitored to ensure that ALXN1720 is safe. The main goal is to check whether new mediations are effective. It will be measured by checking whether patients’ condition has improved compared to when the study started. This will take approximately 26 weeks.

    AustriaDenmarkFranceGermanyItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Sotatercept treatment study for new Pulmonary Hypertension patients

    This study is an important test where doctors are looking at how a drug called Sotatercept can help people struggling with Pulmonary Arterial Hypertension (or PAH for short). The goal is to see whether this drug can delay or prevent the condition from getting worse. PAH makes it really hard for patients to breathe because it affects lungs and heart. The testing process is being done in a fair and careful way. Half of the patients will get the drug, and the others will get a ‘placebo’ which doesnt contain any medicine. The doctors will look at the effect on patients over time. The study is looking specifically at patients who were recently diagnosed with PAH and are at risk for the disease to get worse.

    AustriaBelgiumCzechiaDenmarkFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Testing zimberelimab and domvanalimab with chemotheraphy for lung cancer

    This clinical trial explores the effectiveness of two new medicines, zimberelimab and domvanalimab, in tandem with chemotherapy for patients with untreated metastatic non-small cell lung cancer. The study’s main goal is to compare the impact and success of this combination treatment versus a control group receiving pembrolizumab along with chemotherapy. The hopeful outcome of the trial is to identify whether the new combination of drugs can provide enhanced benefits for the involved patients. Regular health monitoring will occur during the trial to ensure patient safety.

    AustriaBelgiumFranceGermanyItalyNetherlandsPortugalSpainUnited Kingdom
  • Understanding the effect of new therapy in autoinflammatory diseases

    This clinical trial is focused on testing a new drug, MAS825, in patients diagnosed with specific genetic diseases such as AIFEC (Autoinflammation With Infantile Enterocolitis),NLRC4-GoF, XIAP deficiency, or CDC42 mutations. The study, planned to last 3–4 years, consists of three separate phases. Initially, participants will receive the actual drug MAS825. Random assignment will then determine whether patients will continue treatment with MAS825 or switch to a placebo. In the final phase, patients will be monitored for a longer period while continuing to receive MAS825. The main objectives of the study are to evaluate the effectiveness of MAS825 in preventing disease progression, assess its safety profile and determine its impact on patients’ quality of life. Through rigorous observation and analysis, the study is expected to provide valuable information on the potential benefits and risks of treating these genetic diseases with MAS825.

    CzechiaFranceItalySpain
  • Testing new potential drug for blood cancer treatment

    This study investigates the potential treatment BMS-986158 for Myelofibrosis, a type of blood cancer. The research is designed to assess the safety and effectiveness of BMS-986158, both as a standalone treatment and in combination with other drugs like Ruxolitinib or Fedratinib. The study is divided into two main parts: the first part examines the combination of BMS-986158 with either Ruxolitinib or Fedratinib, while the second part evaluates the BMS-986158 in combination with either Ruxolitinib or Fedratinib and BMS-986158 alone. The primary objectives include ensuring the safety of the treatment and observing its ability to prevent the progression of cancer and spleen-related issues.

    FranceGermanyGreeceItalyPolandRomaniaSpain
  • Study on new medicine and immune drugs for hard-to-treat tumors

    The safety and efficacy of a new drug, Zanzalintinib (XL092) is currently evaluated in investigation in a trial designed for individuals with inoperable solid tumors or those that have metastasized. The drug may be administered as a standalone treatment or in combination with other medications designed to stimulate the immune system’s response to combat cancer. The initial phase focuses on determining the appropriate dosage for Zanzalintinib. Subsequently, the trial aims to assess the effectiveness of Zanzalintinib and companion drugs in reducing tumor size and enhancing survival rates. Throughout the study, potential adverse reactions to the drug will also be monitored. During the second stage, the evaluation of Zanzalintinib will be expanded to analyze outcomes in patients with specific cancer types. The objective is to investigate whether the drug leads to a slower progression of cancer and a reduction in tumor size for individuals with these particular types of cancer.

    AustriaBelgiumFranceGermanyItalyPolandSpainUnited Kingdom
  • Study on a new combination therapy for advanced liver cancer

    This study is about trying out a new treatment plan for people with untreated advanced/metastatic hepatocellular carcinoma (HCC). The treatment involves using a combination of three drugs (nivolumab, relatlimab, bevacizumab) compared to a combination of two (nivolumab and bevacizumab). The purpose is to see if adding the third drug can make the treatment more effective, and also to confirm if it’s safe.

    FranceGermanyItalyPolandSpain
  • Studying ustekinumab treatment for Crohn’s perianal fistula

    This is a medical study being conducted to examine how effective a certain medication, called Ustekinumab, can be for people suffering from Crohn’s disease, specifically a subset called perianal Crohn’s. A group of people suffering from moderate to severe forms of this disease will be randomly assigned to receive either the actual medication or a placebo. Their symptoms will then be tracked for a period of 48 weeks to see if the medication helps lessen their symptoms. The end goal is to see whether the drug is useful in stopping all abnormal openings (fistulas) from draining. The study also aims to ensure that the drug doesn’t cause any buildup of more than 2 cm.

    France
  • Studying repotrectinib effect on advanced solid tumors

    In this trial, the researchers are working on a new medicine called Repotrectinib, targeting people with specific types of advanced solid tumors. This medicine might be most helpful if cancer has certain genetic changes, specifically those called ALK, ROS1, or NTRK1-3. It is an early stage of testing Repotrectinib in two parts or phases. During Phase 1,the researchers are trying to find out what the right dose is. It is important to look at the highest dose that can be given without causing too many side effects, and also the dose makes a difference in how the cancer behaves. This phase will also look at how the medication is processed by the body and how it behaves in the system. The second phase will check how well the medicine works in different groups of people, with some details about their cancer and the treatments they have had in the past. It is important to check if the medicine can shrink the tumors and stop them from growing. The researchers will also measure how long these effects last, how quickly these effects occur.

    BelgiumDenmarkFranceGermanyHungaryItalyNetherlandsPolandSpainUnited Kingdom
  • Study on new medicine’s effect and safety in short bowel syndrome treatment

    This trial is designed to check how safe and effective a drug named HM15912 is for people suffering from severe bowel problems, a condition known as short bowel syndrome (SBS). Some patients will get the real drug, while others get placebo – and nobody will know who will get what. The doctors then will check how these injections of HM15912 impact your health, how your body processes the drug, and how the drug affects your body’s functions. The entire process will extend over a period of about 13 months, along with a safety follow-up period.

    BelgiumDenmarkFranceGermanyPoland

See more clinical trials in other cities in France:

.